March 22nd 2024
Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL
December 13th 2021During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.
Read More
In Younger Patients With CLL, Adding Ibrutinib to FCR Combo Shows Promise as Time-Limited Therapy
December 13th 2021Increased rates of complete responses with bone marrow undetectable minimal residual disease were seen with the time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia.
Read More
Superior PFS to FCR in Previously Untreated CLL Seen With Ibrutinib Plus Rituximab
December 13th 2021While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.
Read More
In Older Patients With Chronic Lymphocytic Leukemia Ibrutinib Regimens Yield Superior Efficacy
December 13th 2021Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.
Read More
Implications of the SEQUOIA Trial Results of Zanubrutinib/Venetoclax in CLL/SLL
December 13th 2021Jennifer R. Brown, MD, PhD, discusses the implications of the SEQUOIA trial, which looked at the combination of zanubrutinib and venetoclax for the treatment of patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch
MRD-Guided Ibrutinib and Venetoclax Combination Shows Promise in Relapsed/Refractory CLL
December 11th 2021Data from the phase 2 VISION trial showed that restarting treatment with the combination was feasible in a select group of patients who initially had undetectable MRD after 15 cycles of treatment.
Read More
Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL
November 22nd 2021During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.
Read More
Liso-cel With Concurrent Ibrutinib Shows Early Outcomes Improvement in R/R CLL
November 16th 2021The effects observed with concurrent ibrutinib and lisocabtagene maraleucel in the relapsed or refractory chronic lymphocytic leukeima population included changes in gene signatures related to proliferation, inflammation, and T cell exhaustion.
Read More
Frontline Acalabrutinib Improves Quality-Adjusted Survival in CLL
November 3rd 2021Patients treated with acalabrutinib monotherapy had a significantly longer mean duration of time spent without toxicity compared with those treated with chlorambucil plus obinutuzumab in the phase 3 ELEVATE-TN trial.
Read More